Computational Modeling and Validation of Predicted Diagnostic Peptides for Crimean-Congo's Disease

Elijah Kolawole Oladipo1,2,3, Sola Peter Ogunmodede2,4, Gladys Ayodele Adigun2,5

  • 1Department of Microbiology, Laboratory of Molecular Biology, Immunology and Bioinformatics, Adeleke University, Ede, Osun, Nigeria.

Insights

This study designed a novel synthetic biomarker for Crimean-Congo hemorrhagic fever (CCHF) diagnosis. The biomarker, composed of specific epitopes, shows promise for developing economical and accessible serosurveillance assays.

Area of Science:

  • Immunoinformatics
  • Molecular Biology
  • Virology

Background:

  • Crimean-Congo hemorrhagic fever (CCHF) diagnosis is hindered by the lack of prompt, reliable, and accessible serosurveillance assays.
  • Existing diagnostic methods face challenges due to commercial unavailability and high costs, limiting CCHF eradication efforts.

Purpose of the Study:

  • To design and predict a novel synthetic biomarker for CCHF using immunoinformatics approaches.
  • To identify and combine immunodominant B-cell and T-cell (HTL) interleukin-10 (IL-10) epitopes from CCHF virus proteins.

Main Methods:

  • Epitope prediction and selection from viral glycoprotein, nucleocapsid protein, and RNA-dependent RNA polymerase (RdRp).
  • In silico analysis of biomarker properties including antigenicity, allergenicity, solubility, and physiochemical characteristics.
  • Structural prediction (AlphaFold2), 3D model refinement, codon adaptation, in silico cloning, and molecular docking (HDock) for binding affinity assessment.

Main Results:

  • A multi-epitope synthetic biomarker was designed, predicted to be nonallergenic with good antigenicity and solubility.
  • In silico validations confirmed favorable physiochemical properties, secondary and tertiary structures, and high binding affinity via molecular docking.
  • The designed biomarker demonstrated high potential for use in diagnostic applications.

Conclusions:

  • The in silico designed multi-epitope biomarker holds significant potential for developing cost-effective and accessible CCHF serodiagnostic kits.
  • Further experimental validation is crucial to translate this computational design into a clinically applicable diagnostic tool for CCHF.